Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,616 | 353 | 99.5% |
| Education | $32.71 | 5 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $954.44 | 64 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $728.33 | 23 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $650.32 | 30 | $0 (2020) |
| Amgen Inc. | $546.73 | 23 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $545.65 | 39 | $0 (2020) |
| PFIZER INC. | $412.72 | 23 | $0 (2020) |
| Relypsa, Inc. | $291.75 | 16 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $251.77 | 14 | $0 (2019) |
| Gilead Sciences, Inc. | $238.64 | 13 | $0 (2019) |
| Amarin Pharma Inc. | $227.77 | 14 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $15.21 | 1 | AstraZeneca Pharmaceuticals LP ($15.21) |
| 2020 | $228.20 | 12 | Amgen Inc. ($49.54) |
| 2019 | $2,149 | 103 | Janssen Pharmaceuticals, Inc ($364.39) |
| 2018 | $1,998 | 107 | Boehringer Ingelheim Pharmaceuticals, Inc. ($321.57) |
| 2017 | $2,258 | 135 | Janssen Pharmaceuticals, Inc ($311.43) |
All Payment Transactions
358 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/20/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/05/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | PRADAXA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $27.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/04/2020 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Cardiovascular | ||||||
| 02/27/2020 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/25/2020 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/20/2020 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/18/2020 | Amgen Inc. | Corlanor (Drug), Repatha | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: Cardiology | ||||||
| 02/10/2020 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: Genetic Disease | ||||||
| 02/05/2020 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/21/2020 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $30.42 | General |
| Category: Cardiology | ||||||
| 01/15/2020 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/14/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | PRADAXA (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/08/2020 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.50 | General |
| Category: Cardiovascular | ||||||
| 12/20/2019 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $12.96 | General |
| Category: Cardiovascular | ||||||
| 12/19/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $11.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/18/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | PRADAXA (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/17/2019 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Cardiology | ||||||
| 12/12/2019 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/11/2019 | Lundbeck LLC | NORTHERA (Drug) | Food and Beverage | Cash or cash equivalent | $17.27 | General |
| Category: NEUROLOGY | ||||||
| 12/06/2019 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: Hypertriglyceridemia | ||||||
| 12/04/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/03/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 11/28/2019 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Hypertriglyceridemia | ||||||
| 11/15/2019 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Hypertriglyceridemia | ||||||
| 11/12/2019 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 8 | 382 | 468 | $70,665 | $21,071 |
| 2020 | 11 | 682 | 948 | $126,785 | $39,535 |
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 141 | 184 | $23,184 | $10,913 | 47.1% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 25 | 25 | $22,875 | $4,010 | 17.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 16 | $3,040 | $1,824 | 60.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 34 | 34 | $2,720 | $1,354 | 49.8% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 97 | 106 | $6,890 | $1,081 | 15.7% |
| 93294 | Remote evaluations of single, dual, or multiple lead pacemaker system with qualified health care professional analysis, review, and report, up to 90 days | Office | 2021 | 30 | 47 | $4,418 | $761.21 | 17.2% |
| 93296 | Remote evaluations of single, dual, or multiple lead pacemaker system or implantable defibrillator system with technician review, support and distribution of results, up to 90 days | Office | 2021 | 29 | 45 | $4,590 | $653.80 | 14.2% |
| 93015 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report | Office | 2021 | 11 | 11 | $2,948 | $474.04 | 16.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 191 | 272 | $34,272 | $15,074 | 44.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 46 | 58 | $11,020 | $5,321 | 48.3% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2020 | 23 | 23 | $21,045 | $3,779 | 18.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 45 | 46 | $5,640 | $2,695 | 47.8% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 178 | 202 | $13,130 | $2,648 | 20.2% |
| 93294 | Remote evaluations of single, dual, or multiple lead pacemaker system with qualified health care professional analysis, review, and report, up to 90 days | Office | 2020 | 44 | 116 | $10,904 | $2,646 | 24.3% |
| 93296 | Remote evaluations of single, dual, or multiple lead pacemaker system or implantable defibrillator system with technician review, support and distribution of results, up to 90 days | Office | 2020 | 45 | 117 | $11,934 | $2,373 | 19.9% |
| 93015 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report | Office | 2020 | 35 | 35 | $9,380 | $1,689 | 18.0% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 37 | 41 | $3,280 | $1,496 | 45.6% |
| 93280 | Evaluation, testing, and programming adjustment of permanent dual lead pacemaker system with physician analysis, review, and report | Office | 2020 | 22 | 22 | $3,828 | $996.77 | 26.0% |
| 93279 | Evaluation, testing, and programming adjustment of permanent single lead pacemaker system in one chamber of heart with qualified health care professional analysis, review, and report | Office | 2020 | 16 | 16 | $2,352 | $816.52 | 34.7% |
About Dr. Jared Insel, M.D
Dr. Jared Insel, M.D is a Cardiovascular Disease healthcare provider based in New Britain, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1558369561.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jared Insel, M.D has received a total of $6,648 in payments from pharmaceutical and medical device companies, with $15.21 received in 2021. These payments were reported across 358 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($6,616).
As a Medicare-enrolled provider, Insel has provided services to 1,064 Medicare beneficiaries, totaling 1,416 services with total Medicare billing of $60,606. Data is available for 2 years (2020–2021), covering 19 distinct procedure/service records.
Practice Information
- Specialty Cardiovascular Disease
- Location New Britain, CT
- Active Since 07/13/2005
- Last Updated 07/09/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1558369561
Products in Payments
- XARELTO (Drug) $947.47
- ENTRESTO (Drug) $650.32
- ELIQUIS (Drug) $602.29
- PRADAXA (Drug) $394.88
- JARDIANCE (Drug) $333.45
- Veltassa (Drug) $291.75
- Corlanor (Drug) $289.79
- Repatha (Biological) $256.94
- Vascepa (Drug) $227.77
- CHANTIX (Drug) $216.26
- BRILINTA (Drug) $209.46
- BYSTOLIC (Drug) $202.42
- NORTHERA (Drug) $201.35
- PRALUENT ALIROCUMAB INJECTION (Biological) $158.96
- PRALUENT (Drug) $150.12
- LifeVest (Device) $140.37
- Advisa (Device) $125.51
- Ranexa (Drug) $115.75
- Livalo (Drug) $101.44
- PRALUENT (Biological) $92.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New Britain
Justin Lundbye, M.d, M.D
Cardiovascular Disease — Payments: $31,599
Robert Malkin, Md, MD
Cardiovascular Disease — Payments: $18,479
James St Pierre, Md, MD
Cardiovascular Disease — Payments: $16,130
Robert Borkowski, Md, MD
Cardiovascular Disease — Payments: $12,697
Manny Katsetos, M.d, M.D
Cardiovascular Disease — Payments: $12,050
Jonathan Winkler, M.d, M.D
Cardiovascular Disease — Payments: $6,901